Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data

Boehringer IngelheimThe leading research-driven biopharmaceutical company Boehringer Ingelheim and precision medicine software company Lifebit Biotech, Ltd. (Lifebit) today announce partnership in which Lifebit will support Boehringer Ingelheim in building a scalable data, analytics, and infrastructure platform within its IT environment.

"This platform will play an important part of Boehringer Ingelheim's broader strategy to capture translational disease insights from large external healthcare biobanks and ultimately to accelerate the development of innovative medicines," commented Dr. Jan Nygaard Jensen, SVP and global Head of Computational Biology and Digital Sciences at Boehringer Ingelheim. Lifebit's transformational solutions and services will provide standardization of data sources and types, data curation, identification of data and services that could be migrated to cloud, and federating data connectivity with third parties.

A key element of this partnership involves Lifebit's CloudOS platform - a powerful, secure and cutting-edge platform used by a growing number of research organizations and governments globally, such as Genomics England and The Hong Kong Genome Project. The federated architecture of this platform securely brings analytics and computing tools to the data rather than moving sensitive data around. This promises to unlock the transformational value of biomedical data by enabling seamless integration with world-leading population genomics and disease-focused cohorts. Another key benefit of Lifebit's CloudOS will be the provision of powerful analytic capabilities and global biobank connections to build a secure "dataland" for analytics and research.

This collaboration follows on the partnership announced in 2021 on utilizing the Lifebit REAL platform to accelerate detection of the latest disease outbreaks including transboundary diseases and emerging pathogens, such as COVID-19.

Lifebit CEO Dr. Maria Chatzou Dunford shared: "We are thrilled to contribute to Boehringer Ingelheim’s vision of harnessing the power of external biobanks and large-scale clinico-genomic data to transform R&D. We are excited to see how our technology and global biobank partnerships can transform research capabilities for Boehringer Ingelheim and deliver powerful impacts for clinical development pipelines across disease areas."

"We are continuously on the lookout for new opportunities to be able to deliver faster, better and safer solutions. Therefore, partnering with Lifebit, one of our partners in this area, is so critical as data and digital technologies can feed into meaningful scientific exploration, accelerate patient benefits, and ultimately lead to improved health," added Markus Schümmelfeder, Head of IT at Boehringer Ingelheim.

About Lifebit Biotech, Ltd.

Lifebit builds enterprise data platforms for use by organisations with complex and sensitive biomedical datasets. Lifebit’s patented federated technology securely unlocks access to biomedical data. From providing Trusted Research Environments for national precision medicine programmes to enabling pharmaceutical companies to discover new drug targets faster, Lifebit empowers customers to transform how they leverage sensitive biomedical data.

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...